Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lilly and Amylin reach agreement to terminate diabetes alliance

Nov. 9, 2011

Presentations provide further phase II data on lesinurad in gout

Nov. 9, 2011

Recordati's Normosang approved in Russia

Nov. 8, 2011

Novo Nordisk reports results from Japanese phase IIIa trial of DegludecPlus

Nov. 8, 2011

Evolva clear to begin phase IIa development of EV-077 in diabetic complications

Nov. 8, 2011

NPS Pharmaceuticals reports topline results from phase III REPLACE study

Nov. 8, 2011

Synageva BioPharma and Trimeris complete merger

Nov. 8, 2011

Arena Pharmaceuticals patents new molecules for type 2 diabetes and obesity

Nov. 7, 2011

New GPR119 receptor agonists claimed

Nov. 7, 2011

FDA accepts VIVUS' resubmitted Qnexa NDA

Nov. 4, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...